Sign In
Buy RXRX
$3.52
+0.180 (+5.39%)
At Close: Jun 26, 2026
Strength Seen in Recursion Pharmaceuticals (RXRX): Can Its 27.7% Jump Turn into More Strength?
10:10am, Monday, 14'th Apr 2025
Recursion Pharmaceuticals (RXRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further str
Why Recursion Pharmaceuticals Stock Is Skyrocketing Today
11:11am, Friday, 11'th Apr 2025
Shares of Recursion Pharmaceuticals (RXRX 17.52%) were skyrocketing around 20% higher as of 11 a.m. ET on Friday.
RXRX Doses First Patient in Early-Stage B-Cell Lymphomas Study
11:05am, Wednesday, 09'th Apr 2025
Recursion Pharmaceuticals doses the first patient in a phase I study of its investigational candidate, REC-3565, for treating B-cell lymphomas.
Recursion and Enamine Release New AI-Enabled Targeted Compound Libraries
08:00am, Wednesday, 09'th Apr 2025
Kyiv, Ukraine and Salt Lake City, UT, April 09, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced
Why Biotech Stocks Such as Biohaven, Recursion Pharmaceuticals, and CRISPR Therapeutics Plunged in March
09:30am, Thursday, 03'rd Apr 2025
Shares of early-stage biotech stocks, including Biohaven (BHVN -6.50%), Recursion Pharmaceuticals (RXRX -4.92%), and CRISPR Therapeutics (CRSP -2.05%), plunged in March, with the stocks down 35.3%, 29
Recursion to Participate in Upcoming Investor Conference
08:00am, Tuesday, 01'st Apr 2025
Salt Lake City, UT, April 01, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced today its particip
Why Biotech Stocks Like Recursion Pharmaceuticals, CRISPR Therapeutics, and Summit Therapeutics Plunged Today
03:25pm, Monday, 31'st Mar 2025
Shares of biotechnology stocks such as Recursion Pharmaceuticals (RXRX -8.18%), Summit Therapeutics (SMMT -4.28%), and CRISPR Therapeutics AG (CRSP -8.06%) plunged on Monday, down 9.4%, 5.6%, and 9.2%
Should Investors Buy These 2 Beaten-Down Artificial Intelligence (AI) Healthcare Stocks?
09:30am, Sunday, 30'th Mar 2025
Artificial intelligence (AI) is changing the world. Corporations are racing to establish themselves as leaders in the field, while investors want to cash in by putting their hard-earned money into the
Nvidia Has 81% of Its $304 Million Stock Portfolio Invested in 3 Groundbreaking AI Stocks
04:30am, Sunday, 30'th Mar 2025
The semiconductor giant Nvidia (NVDA -1.51%) is quite the company, developing high-end graphics processing units (GPUs) that help power artificial intelligence (AI) applications. Many investors view N
Why Recursion Pharmaceuticals (RXRX) Dipped More Than Broader Market Today
06:56pm, Thursday, 20'th Mar 2025
In the closing of the recent trading day, Recursion Pharmaceuticals (RXRX) stood at $6.48, denoting a -1.52% change from the preceding trading day.
Recursion Pharma Down 37% in a Month: Buy, Sell or Hold the Stock?
11:00am, Tuesday, 18'th Mar 2025
Despite the current downward trend of RXRX, one should retain the stock for long-term gains due to the significant potential of its AI-driven drug discovery technology.
Why Recursion Pharmaceuticals Stock Is Sinking Today
11:47am, Monday, 10'th Mar 2025
Shares of Recursion Pharmaceuticals (RXRX -5.54%) were sinking 8.2% lower as of 10:57 a.m. ET on Monday.
Is This Beaten-Down Artificial Intelligence (AI) Stock a Buy?
10:02am, Saturday, 08'th Mar 2025
The artificial intelligence (AI) industry has been on a tear in the past two years, and judging by analyst estimates, it's just the beginning. AI-related sales will continue to soar in the coming year
4 Things You Need to Know if You Buy Recursion Pharmaceuticals Stock Today
08:30am, Friday, 07'th Mar 2025
Investors looking for an exciting clinical-stage biotech start-up with enormous potential should be paying close attention to Recursion Pharmaceuticals (RXRX -5.17%).
This Biotech Stock Could Be the Best Investment of the Decade
04:55am, Friday, 07'th Mar 2025
It's typically not too difficult to find a company that should perform well for the next couple of years. Two years isn't very long, after all, and the stock market's dynamics tend to dictate performa
